Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Melanoma 5Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

pembrolizumab 29avelumab 21Nivolumab 20Ipilimumab 10Radiotherapy 9Cyclophosphamide 9atezolizumab 8cemiplimab 7fludarabine 6Specimen Handling 6durvalumab 5aldesleukin 5Radiation 5Magnetic Resonance Spectroscopy 5Interleukin-2 5Biopsy 5talimogene laherparepvec 4ALT-803 4poly ICLC 3Radiosurgery 3Etoposide 3Cisplatin 3Carboplatin 3CTLA-4 Antigen 3Bevacizumab 3prednylidene 2lutetium Lu 177 dotatate 2fludarabine phosphate 2domatinostat 2deltacortene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × oblimersen × Clear all
NCT00079131 2013-06-04

Oblimersen in Treating Patients With Merkel Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡